The research suggests that maintaining hydroxychloroquine (HCQ) blood levels between 750-1200 ng/mL can lead to a 71% lower odds of active lupus and a 26% reduction in flare-ups over 9 months. Guidelines for HCQ dosing may not align with efficacy needs, emphasizing the importance of personalized dosing. Monitoring HCQ blood levels is crucial, especially for patients with chronic kidney disease (CKD) stage 3 or higher. The study highlights the need for individualized dosing to maximize efficacy and minimize toxicity risks.
다른 언어로
소스 콘텐츠 기반
www.medscape.com
핵심 통찰 요약
by Marcia Frell... 게시일 www.medscape.com 09-12-2023
https://www.medscape.com/viewarticle/996340더 깊은 질문